Zydus Cadila also launches its generic Tenglyn tablets, Gliptins, in the Indian market for Rs 7 per tablet
Mankind Pharma has launched an anti-diabetic product ‘Dynaglipt’ targeting the middle class and rural diabetic patients. The company has launched anti-diabetic product for the diabetic patients targeting the middle class and rural diabetic patients, so as to cater to this growing epidemic, Mankind Pharma said in a statement.
The product, which has been approved by Drug Controller General (India), is priced at nearly Rs 600 for 30 days therapy to a patient. Mankind Pharma aims to achieve a revenue of Rs 4,200 crore this year and with the launch of Dynaglipt, the diabetes segment would contribute Rs 200 crore to the revenue, the company said.
Recently, Zydus Cadila launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in the Indian market. Tenglyn is being priced at just Rs 7 per tablet.